Biomedicines (Sep 2023)

An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)

  • Ciara Murphy,
  • Glòria Gornés Pons,
  • Anna Keogh,
  • Lisa Ryan,
  • Lorraine McCarra,
  • Chris Maria Jose,
  • Shagun Kesar,
  • Siobhan Nicholson,
  • Gerard J. Fitzmaurice,
  • Ronan Ryan,
  • Vincent Young,
  • Sinead Cuffe,
  • Stephen P. Finn,
  • Steven G. Gray

DOI
https://doi.org/10.3390/biomedicines11092576
Journal volume & issue
Vol. 11, no. 9
p. 2576

Abstract

Read online

The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in any great detail in cancer. Using a series of standard biological and bioinformatics approaches we investigated JADE2 expression in surgically resected non-small cell lung cancer (NSCLC) for both mRNA and protein to examine for correlations between JADE2 expression and overall survival. Additional correlations were identified using bioinformatic analyses on multiple online datasets. Our analysis demonstrates that JADE2 expression is significantly altered in NSCLC. High expression of JADE2 is associated with a better 5-year overall survival. Links between JADE2 mRNA expression and a number of mutated genes were identified, and associations between JADE2 expression and tumor mutational burden and immune cell infiltration were explored. Potential new drugs that can target JADE2 were identified. The results of this biomarker-driven study suggest that JADE2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients into various therapeutically targetable options.

Keywords